Socioeconomic Burden of Psoriatic Arthritis in Hong Kong: Direct and Indirect Costs and the Influence of Disease Pattern
- 1 April 2010
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 37 (6) , 1214-1220
- https://doi.org/10.3899/jrheum.090988
Abstract
Objective. To estimate the direct costs and indirect costs of patients with psoriatic arthritis (PsA) in Hong Kong. Methods. A retrospective cost-of-illness study was performed on 125 patients with PsA. Participants completed questionnaires on demographics, employment status, and out of pocket expenses. Health resources consumption was recorded by chart review and patient self-report questionnaire. Patients were grouped according to disease pattern, i.e., peripheral and axial disease. Multiple regression was used to determine the predictors of the costs. Results. The average annual direct costs were $4,141 (2006 US dollars) per patient. Costs of inpatient care accounted for 27% of direct costs, followed by costs of visits to healthcare providers (25%). The estimated average indirect costs were $3,127 per patient-year. Forty-eight (42%) patients had no indirect costs. Sixty percent of patients with peripheral disease were still employed, compared to 39% of patients with axial disease. Patients with axial disease had almost twice the indirect costs compared to those with peripheral disease (p = 0.005). Increased pain and poor function were independently associated with increased direct costs. Worse physical health status, determined by indirect costs borne by the patient, and poor function and old age predicted high costs. Conclusion. PsA imposes substantial economic burden. Pain and function are significantly associated with costs. Improvements in treatments to reduce pain and restore function are likely to reduce the costs incurred by these patients.Keywords
This publication has 21 references indexed in Scilit:
- Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong KongRheumatology, 2008
- The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapyRheumatology, 2008
- Costs and quality of life of patients with ankylosing spondylitis in Hong KongRheumatology, 2008
- Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitorsAnnals of the Rheumatic Diseases, 2006
- Cost-of-illness analysisHealth Policy, 2006
- Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Arthritis & Rheumatism, 2005
- Current concepts and new developments in the treatment of psoriatic arthritisRheumatology, 2003
- A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experienceRheumatology, 2003
- Quality of Life and Prevalence of Arthritis Reported by 5,795 Members of the Nordic Psoriasis AssociationsActa Dermato-Venereologica, 2002
- Medical informatics—the state of the art in the Hospital AuthorityInternational Journal of Medical Informatics, 2001